Administer triamcinolone with caution

Article

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration.

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration, according to the results of a study published online ahead of print by Clinical Ophthalmology.

M. Selim kocabora and co-workers from the Vakif Gureba Education and Research Hospital, Istanbul, Turkey reviewed the records of 122 patients (147 eyes) who had undergone IVTA treatment between 2003 and 2006.

The mean IOP following IVTA injection was statistically significantly higher than pre-injection IOP. Important IOP elevations were observed mostly in the first and second months. In 40 eyes (27.7%), topical anti-glaucomatous therapy was required and seven later required surgical intervention to lower IOP.

The researchers think that IVTA should be administered only after careful planning.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.